Who are Restasis (cyclosporine 0.05%)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sandimmune, CYCLOSPORINE, cyclosporine or tacrolimus, tacrolimus ointment 0.1%, rhTPO combined with Herombopag + CsA, Everolimus+Tacrolimus+Prednisone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/restasis-cyclosporine-0-05.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Restasis (cyclosporine 0.05%) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Restasis (cyclosporine 0.05%) (Restasis (cyclosporine 0.05%)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: immunosuppressant. Area: Ophthalmology.

phase 3 immunosuppressant calcineurin Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Restasis (cyclosporine 0.05%) (Restasis (cyclosporine 0.05%)) — DH Bio Co., Ltd.. Restasis works by increasing tear production in patients with dry eye syndrome.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Restasis (cyclosporine 0.05%) TARGET	Restasis (cyclosporine 0.05%)	DH Bio Co., Ltd.	phase 3	immunosuppressant	calcineurin
Sandimmune	cyclosporine	Novartis AG (originally Sandoz)	marketed	Calcineurin inhibitor (immunosuppressant)	Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2	1983-11-14
CYCLOSPORINE	CYCLOSPORINE		marketed	Calcineurin Inhibitor Immunosuppressant [EPC]	calcineurin	1983-01-01
cyclosporine or tacrolimus	cyclosporine or tacrolimus	Russian Academy of Medical Sciences	marketed	Calcineurin inhibitor	Calcineurin (protein phosphatase 2B)
tacrolimus ointment 0.1%	tacrolimus ointment 0.1%	Hospital de Clinicas de Porto Alegre	marketed	Calcineurin inhibitor	Calcineurin (via FKBP12 binding)
rhTPO combined with Herombopag + CsA	rhTPO combined with Herombopag + CsA	Peking Union Medical College Hospital	marketed	Thrombopoietin receptor agonist combination with immunosuppressant	Thrombopoietin receptor (MPL); calcineurin (CsA target)
Everolimus+Tacrolimus+Prednisone	Everolimus+Tacrolimus+Prednisone	Fundação Pró Rim	marketed	Immunosuppressive combination therapy	mTOR (everolimus), calcineurin (tacrolimus), glucocorticoid receptor (prednisone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-11-03 — Sandimmune · 8298568 · Formulation · US
2029-06-02 — Sandimmune · 9132071 · Formulation · US
2030-12-13 — Sandimmune · 8614178 · Formulation · US
2031-02-25 — Sandimmune · 8292129 · Formulation · US
2032-04-16 — Sandimmune · 8561859 · Formulation · US
2033-08-23 — Sandimmune · 8980839 · Formulation · US
2033-08-23 — Sandimmune · 10441630 · Formulation · US
2033-08-23 — Sandimmune · 9937225 · Formulation · US
2034-02-07 — Sandimmune · 9676525 · Formulation · US
2034-05-11 — Sandimmune · 9669974 · Formulation · US
2036-09-29 — Sandimmune · 12496326 · Method of Use · US
2037-02-28 — Sandimmune · 11951153 · Method of Use · US
2037-02-28 — Sandimmune · 10918694 · Formulation · US
2037-09-22 — Sandimmune · 10813976 · Formulation · US
2038-11-20 — Sandimmune · 11154513 · Formulation · US
2039-10-11 — Sandimmune · 11413323 · Method of Use · US
2042-04-01 — Sandimmune · 12059449 · Formulation · US

Sponsor landscape (immunosuppressant class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Centre Hospitalier Universitaire, Amiens · 1 drug in this class
DH Bio Co., Ltd. · 1 drug in this class
Glenmark Pharmaceuticals Ltd. India · 1 drug in this class
Palvella Therapeutics, Inc. · 1 drug in this class
Pfizer · 1 drug in this class
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · 1 drug in this class
University of California, San Francisco · 1 drug in this class
Vanderbilt-Ingram Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Restasis (cyclosporine 0.05%) — Competitive Intelligence Brief. https://druglandscape.com/ci/restasis-cyclosporine-0-05. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab